Literature DB >> 32164272

The Biological Role of Apurinic/Apyrimidinic Endonuclease1/Redox Factor-1 as a Therapeutic Target for Vascular Inflammation and as a Serologic Biomarker.

Yu Ran Lee1,2, Hee Kyoung Joo1,2, Byeong Hwa Jeon1,2.   

Abstract

Endothelial dysfunction promotes vascular inflammation by inducing the production of reactive oxygen species and adhesion molecules. Vascular inflammation plays a key role in the pathogenesis of vascular diseases and atherosclerotic disorders. However, whether there is an endogenous system that can participate in circulating immune surveillance or managing a balance in homeostasis is unclear. Apurinic/apyrimidinic endonuclease 1/redox factor-1 (henceforth referred to as APE1/Ref-1) is a multifunctional protein that can be secreted from cells. It functions as an apurinic/apyrimidinic endonuclease in the DNA base repair pathway and modulates redox status and several types of transcriptional factors, in addition to its anti-inflammatory activity. Recently, it was reported that the secretion of APE1/Ref-1 into the extracellular medium of cultured cells or its presence in the plasma can act as a serological biomarker for certain disorders. In this review, we summarize the possible biological functions of APE1/Ref-1 according to its subcellular localization or its extracellular secretions, as therapeutic targets for vascular inflammation and as a serologic biomarker.

Entities:  

Keywords:  APE1/Ref-1; cardiovascular diseases; endothelial dysfunction; serological biomarkers; subcellular localization; vascular inflammation

Year:  2020        PMID: 32164272     DOI: 10.3390/biomedicines8030057

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  8 in total

Review 1.  Extracellular vesicles in vascular remodeling.

Authors:  Chao Ye; Fen Zheng; Nan Wu; Guo-Qing Zhu; Xiu-Zhen Li
Journal:  Acta Pharmacol Sin       Date:  2022-01-12       Impact factor: 7.169

2.  APE1/Ref-1 - One Target with Multiple Indications: Emerging Aspects and New Directions.

Authors:  Mahmut Mijit; Rachel Caston; Silpa Gampala; Melissa L Fishel; Jill Fehrenbacher; Mark R Kelley
Journal:  J Cell Signal       Date:  2021

3.  Bioinformatic Prediction of Signaling Pathways for Apurinic/Apyrimidinic Endodeoxyribonuclease 1 (APEX1) and Its Role in Cholangiocarcinoma Cells.

Authors:  Doungdean Tummanatsakun; Tanakorn Proungvitaya; Sittiruk Roytrakul; Siriporn Proungvitaya
Journal:  Molecules       Date:  2021-04-29       Impact factor: 4.411

Review 4.  Raloxifene as Treatment for Various Types of Brain Injuries and Neurodegenerative Diseases: A Good Start.

Authors:  Leo Veenman
Journal:  Int J Mol Sci       Date:  2020-10-14       Impact factor: 5.923

5.  Ref-1 protects against FeCl3-induced thrombosis and tissue factor expression via the GSK3β-NF-κB pathway.

Authors:  Ikjun Lee; Harsha Nagar; Seonhee Kim; Su-Jeong Choi; Shuyu Piao; Moonsang Ahn; Byeong Hwa Jeon; Sang-Ha Oh; Shin Kwang Kang; Cuk-Seong Kim
Journal:  Korean J Physiol Pharmacol       Date:  2021-01-01       Impact factor: 2.016

6.  Changes in the Plasma Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1(APE1/Ref-1) Level during Cancer Surgery: An Observational Study.

Authors:  Yumin Jo; Yeojung Kim; Eunhye Park; Yuran Lee; Jiyeon Kim; Minwoong Kang; Jaesung Lim; Insang Song; Chaeseong Lim; Byeonghwa Jeon
Journal:  Medicina (Kaunas)       Date:  2021-11-21       Impact factor: 2.430

Review 7.  APE1/Ref-1 Role in Inflammation and Immune Response.

Authors:  Thais Teixeira Oliveira; Leonam Gomes Coutinho; Laysa Ohana Alves de Oliveira; Ana Rafaela de Souza Timoteo; Guilherme Cavalcanti Farias; Lucymara Fassarella Agnez-Lima
Journal:  Front Immunol       Date:  2022-02-28       Impact factor: 7.561

Review 8.  A Dual Face of APE1 in the Maintenance of Genetic Stability in Monocytes: An Overview of the Current Status and Future Perspectives.

Authors:  Gabriela Betlej; Ewelina Bator; Antoni Pyrkosz; Aleksandra Kwiatkowska
Journal:  Genes (Basel)       Date:  2020-06-11       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.